Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2008

01-07-2008 | Original Paper

Tumour Necrosis Factor Alpha in Segmental Colitis Associated with Diverticula

Authors: Enzo Ierardi, Gianmichele Meucci, Cesare Hassan, Angelo Zullo, Gianni Imperiali, Vincenzo De Francesco, Carmine Panella, Sergio Morini, Giorgio Minoli

Published in: Digestive Diseases and Sciences | Issue 7/2008

Login to get access

Abstract

The pathogenesis of segmental colitis associated with diverticula (SCAD) is unclear, but tumour necrosis factor alpha (TNF-α) has been shown to play a pivotal role in the pathogenesis of inflammatory bowel diseases. The aim of this study was to assess TNF-α levels in patients with SCAD. In a post hoc analysis of a prospective multicenter study, tissue samples from 13 patients diagnosed with SCAD were subjected to histological analyses. The severity of the inflammation was assessed by means of a histological score and histomorphometry (number of inflammatory cells/mm2). Immunohistochemical staining with an antibody against TNF-α was performed on all biopsies and the degree of staining expressed as the percentage of positive stromal cells/1000 counted (TNF-α score). Matched patients with irritable bowel syndrome (IBS) were used as controls. Over-expression of TNF-α was found in all SCAD patients (38.6 ± 10.4%), and it was associated with a high histological score (2.5 ± 0.5) and neutrophil cell count (16.3 ± 3/mm2). These values were distinctly higher than those found in the IBS controls. Our data suggest that TNF-α activity is involved in SCAD pathogenesis, similarly to what occurs in Crohn’s disease and ulcerative colitis.
Literature
1.
go back to reference Hughes LE (1969) Post-mortem survey of diverticular disease of the colon. 1. Diverticulosis and diverticulitis. Gut 10:336–344PubMedCrossRef Hughes LE (1969) Post-mortem survey of diverticular disease of the colon. 1. Diverticulosis and diverticulitis. Gut 10:336–344PubMedCrossRef
2.
go back to reference Imperiali G, Meucci G, Alvisi C et al (2000) Segmental colitis associated with diverticula: a prospective study. Am J Gastroenterol 95:1014–1016PubMedCrossRef Imperiali G, Meucci G, Alvisi C et al (2000) Segmental colitis associated with diverticula: a prospective study. Am J Gastroenterol 95:1014–1016PubMedCrossRef
3.
go back to reference Koutroubakis IE, Antoniou P, Tzardi M et al (2005) The spectrum of segmental colitis associated with diverticulosis. Int J Colorectal Dis 20:28–32PubMedCrossRef Koutroubakis IE, Antoniou P, Tzardi M et al (2005) The spectrum of segmental colitis associated with diverticulosis. Int J Colorectal Dis 20:28–32PubMedCrossRef
4.
5.
go back to reference Shepherd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802PubMedCrossRef Shepherd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802PubMedCrossRef
6.
go back to reference Peppercorn MA (1992) Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol 87:609–612PubMed Peppercorn MA (1992) Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol 87:609–612PubMed
7.
go back to reference Reimund JM, Wittersheim C, Dumont S et al (1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39:684–689PubMedCrossRef Reimund JM, Wittersheim C, Dumont S et al (1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39:684–689PubMedCrossRef
8.
go back to reference Murch SH, Lamkin VA, Savage MO et al (1991) Serum concentrations of tumour necrosis factor a in childhood chronic inflammatory bowel disease. Gut 32:913–917PubMedCrossRef Murch SH, Lamkin VA, Savage MO et al (1991) Serum concentrations of tumour necrosis factor a in childhood chronic inflammatory bowel disease. Gut 32:913–917PubMedCrossRef
9.
go back to reference Braegger CP, Nicholls S, Murch SH et al (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91PubMedCrossRef Braegger CP, Nicholls S, Murch SH et al (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91PubMedCrossRef
10.
go back to reference Reinecker H-C, Steffen M, Witthoeft T et al (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1b by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 94:174–181PubMedCrossRef Reinecker H-C, Steffen M, Witthoeft T et al (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1b by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 94:174–181PubMedCrossRef
11.
go back to reference Plevy SE, Landers CJ, Prehn J et al (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 159:6276–6282PubMed Plevy SE, Landers CJ, Prehn J et al (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 159:6276–6282PubMed
12.
go back to reference Berner B, Akca D, Jung T et al (2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27:1128–1135PubMed Berner B, Akca D, Jung T et al (2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27:1128–1135PubMed
13.
go back to reference Murch SH, Braegger CP, Walker-Smith JA et al (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709PubMedCrossRef Murch SH, Braegger CP, Walker-Smith JA et al (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709PubMedCrossRef
14.
go back to reference Hassan C, Ierardi E, Burattini O et al (2007) tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 39:811–817PubMedCrossRef Hassan C, Ierardi E, Burattini O et al (2007) tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 39:811–817PubMedCrossRef
15.
go back to reference Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Mol Immunol 30:1443–1453PubMedCrossRef Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Mol Immunol 30:1443–1453PubMedCrossRef
16.
go back to reference Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476PubMedCrossRef Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476PubMedCrossRef
17.
go back to reference Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRef Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRef
18.
go back to reference Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulising Crohn’s disease. N Engl J Med 350:876–885PubMedCrossRef Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulising Crohn’s disease. N Engl J Med 350:876–885PubMedCrossRef
19.
go back to reference Baert FJ, D’Haens GR, Peeters M et al (1999) tumour necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28PubMedCrossRef Baert FJ, D’Haens GR, Peeters M et al (1999) tumour necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28PubMedCrossRef
20.
go back to reference Hassan C, Zullo A, Ierardi E et al (2006) Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Gut 55:589–590PubMedCrossRef Hassan C, Zullo A, Ierardi E et al (2006) Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Gut 55:589–590PubMedCrossRef
21.
go back to reference Imperiali G, Terpin MM, Meucci G et al (2006) Segmental colitis associated with diverticula: a 7-year follow-up study. Endoscopy 38:610–612PubMedCrossRef Imperiali G, Terpin MM, Meucci G et al (2006) Segmental colitis associated with diverticula: a 7-year follow-up study. Endoscopy 38:610–612PubMedCrossRef
22.
go back to reference Morson BC, Dawson IMP (1979) Gastro-intestinal pathology, 2nd edn. Blackwell Scientific Publications, Oxford, pp 530–533 Morson BC, Dawson IMP (1979) Gastro-intestinal pathology, 2nd edn. Blackwell Scientific Publications, Oxford, pp 530–533
23.
go back to reference Ierardi E, Monno RA, Gentile A et al (2001) Helicobacter heilmannii gastritis: a histological and immunohistochemical trait. J Clin Pathol 54:774–777PubMed Ierardi E, Monno RA, Gentile A et al (2001) Helicobacter heilmannii gastritis: a histological and immunohistochemical trait. J Clin Pathol 54:774–777PubMed
Metadata
Title
Tumour Necrosis Factor Alpha in Segmental Colitis Associated with Diverticula
Authors
Enzo Ierardi
Gianmichele Meucci
Cesare Hassan
Angelo Zullo
Gianni Imperiali
Vincenzo De Francesco
Carmine Panella
Sergio Morini
Giorgio Minoli
Publication date
01-07-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0086-9

Other articles of this Issue 7/2008

Digestive Diseases and Sciences 7/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine